Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTMX NASDAQ:IMNM NASDAQ:KOD NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$4.00-0.1%$4.66$0.91▼$8.21$681.60M2.185.74 million shs1.70 million shsIMNMImmunome$22.42+1.0%$21.94$7.39▼$27.65$2.54B2.111.38 million shs108,152 shsKODKodiak Sciences$42.32-3.1%$34.96$2.81▼$47.84$2.63B2.32964,533 shs165,717 shsTARSTarsus Pharmaceuticals$62.43-2.4%$68.72$38.51▼$85.25$2.68B0.52574,562 shs50,645 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics-3.15%-5.21%-6.98%-29.45%+311.10%IMNMImmunome-4.64%-3.27%+2.83%-10.81%+198.65%KODKodiak Sciences-4.82%+0.46%+4.52%+89.58%+1,029.56%TARSTarsus Pharmaceuticals-1.24%+0.55%-6.98%-1.02%+35.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$4.00-0.1%$4.66$0.91▼$8.21$681.60M2.185.74 million shs1.70 million shsIMNMImmunome$22.42+1.0%$21.94$7.39▼$27.65$2.54B2.111.38 million shs108,152 shsKODKodiak Sciences$42.32-3.1%$34.96$2.81▼$47.84$2.63B2.32964,533 shs165,717 shsTARSTarsus Pharmaceuticals$62.43-2.4%$68.72$38.51▼$85.25$2.68B0.52574,562 shs50,645 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics-3.15%-5.21%-6.98%-29.45%+311.10%IMNMImmunome-4.64%-3.27%+2.83%-10.81%+198.65%KODKodiak Sciences-4.82%+0.46%+4.52%+89.58%+1,029.56%TARSTarsus Pharmaceuticals-1.24%+0.55%-6.98%-1.02%+35.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTMXCytomX Therapeutics 2.80Moderate Buy$13.44236.53% UpsideIMNMImmunome 2.91Moderate Buy$33.4549.22% UpsideKODKodiak Sciences 2.50Moderate Buy$35.43-16.27% DownsideTARSTarsus Pharmaceuticals 2.78Moderate Buy$90.6745.23% UpsideCurrent Analyst Ratings BreakdownLatest CTMX, TARS, KOD, and IMNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026IMNMImmunome Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/4/2026TARSTarsus Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$88.004/24/2026TARSTarsus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$105.00 ➝ $98.004/21/2026IMNMImmunome Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026TARSTarsus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026KODKodiak Sciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $80.003/27/2026KODKodiak Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.00 ➝ $58.003/23/2026CTMXCytomX Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $12.003/19/2026CTMXCytomX Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)3/19/2026CTMXCytomX Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $16.003/18/2026CTMXCytomX Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $16.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTMXCytomX Therapeutics$76.20M8.92N/AN/A$0.58 per share6.89IMNMImmunome$6.94M365.86N/AN/A$5.75 per share3.90KODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/ATARSTarsus Pharmaceuticals$451.36M5.95N/AN/A$8.09 per share7.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTMXCytomX Therapeutics-$17.37M-$0.04N/AN/AN/A-22.79%-19.77%-11.91%N/AIMNMImmunome-$212.39M-$2.42N/AN/AN/AN/A-57.61%-52.39%5/11/2026 (Estimated)KODKodiak Sciences-$229.97M-$4.32N/AN/AN/AN/A-255.37%-81.82%5/13/2026 (Estimated)TARSTarsus Pharmaceuticals-$66.42M-$1.62N/A23.83N/A-9.02%-14.32%-9.10%N/ALatest CTMX, TARS, KOD, and IMNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A5/11/2026Q1 2026IMNMImmunome-$0.60N/AN/AN/A$0.22 millionN/A5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million5/6/2026Q1 2026TARSTarsus Pharmaceuticals-$0.4003-$0.16+$0.2403-$0.16$149.60 million$162.05 million3/31/2026Q4 2025KODKodiak Sciences-$1.02-$1.04-$0.02-$1.04N/AN/A3/16/2026Q4 2025CTMXCytomX Therapeutics-$0.08-$0.22-$0.14-$0.22$7.33 million$0.66 million3/3/2026Q4 2025IMNMImmunome-$0.65-$0.75-$0.10-$0.75$0.79 millionN/A2/23/2026Q4 2025TARSTarsus Pharmaceuticals-$0.19-$0.20-$0.01-$0.20$144.56 million$151.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTMXCytomX TherapeuticsN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTMXCytomX TherapeuticsN/A3.093.09IMNMImmunomeN/A14.6914.69KODKodiak SciencesN/A4.724.72TARSTarsus Pharmaceuticals0.213.853.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTMXCytomX Therapeutics67.77%IMNMImmunome44.58%KODKodiak Sciences89.06%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipCTMXCytomX Therapeutics6.60%IMNMImmunome7.21%KODKodiak Sciences45.90%TARSTarsus Pharmaceuticals8.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTMXCytomX Therapeutics170170.19 million158.96 millionOptionableIMNMImmunome40113.25 million105.09 millionOptionableKODKodiak Sciences9062.16 million33.63 millionOptionableTARSTarsus Pharmaceuticals5043.02 million39.17 millionOptionableCTMX, TARS, KOD, and IMNM HeadlinesRecent News About These CompaniesWhat is HC Wainwright's Estimate for TARS FY2027 Earnings?2 hours ago | marketbeat.comLifeSci Capital Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)3 hours ago | theglobeandmail.comWhat is Lifesci Capital's Forecast for TARS Q1 Earnings?3 hours ago | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from AnalystsMay 8 at 3:09 AM | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesMay 7 at 5:00 PM | globenewswire.comTarsus Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMay 7 at 10:32 AM | finance.yahoo.comLifesci Capital Has Pessimistic Outlook of TARS Q4 EarningsMay 7 at 8:16 AM | marketbeat.comTarsus Pharmaceuticals Q1 Earnings Call HighlightsMay 7 at 2:06 AM | marketbeat.comTarsus Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 7 at 1:37 AM | seekingalpha.comTarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call TranscriptMay 6 at 10:02 PM | seekingalpha.comTarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue EstimatesMay 6 at 7:31 PM | zacks.comTarsus Reports First Quarter 2026 Financial Results and Recent Business AchievementsMay 6 at 6:41 PM | finance.yahoo.comTarsus Pharmaceuticals (NASDAQ:TARS) Issues Earnings Results, Beats Expectations By $0.27 EPSMay 6 at 4:26 PM | marketbeat.comTarsus Reports First Quarter 2026 Financial Results and Recent Business AchievementsMay 6 at 4:05 PM | globenewswire.comHC Wainwright Issues Pessimistic Outlook for TARS EarningsMay 6 at 7:58 AM | marketbeat.comTarsus Pharmaceuticals, Inc. Q1 2026 earnings previewMay 5 at 10:40 PM | msn.comTarsus Pharmaceuticals' (TARS) Buy Rating Reaffirmed at HC WainwrightMay 5 at 3:27 AM | americanbankingnews.comTarsus Pharmaceuticals (NASDAQ:TARS) Earns Buy Rating from HC WainwrightMay 4, 2026 | marketbeat.comPictet Asset Management Holding SA Sells 36,069 Shares of Tarsus Pharmaceuticals, Inc. $TARSMay 4, 2026 | marketbeat.comD.A. Davidson & CO. Takes $1.49 Million Position in Tarsus Pharmaceuticals, Inc. $TARSMay 3, 2026 | marketbeat.comJennison Associates LLC Sells 374,511 Shares of Tarsus Pharmaceuticals, Inc. $TARSApril 30, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026CTMX, TARS, KOD, and IMNM Company DescriptionsCytomX Therapeutics NASDAQ:CTMX$4.00 -0.01 (-0.13%) As of 11:19 AM Eastern This is a fair market value price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Immunome NASDAQ:IMNM$22.42 +0.23 (+1.04%) As of 11:19 AM Eastern This is a fair market value price provided by Massive. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Kodiak Sciences NASDAQ:KOD$42.32 -1.37 (-3.13%) As of 11:19 AM Eastern This is a fair market value price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Tarsus Pharmaceuticals NASDAQ:TARS$62.43 -1.53 (-2.39%) As of 11:19 AM Eastern This is a fair market value price provided by Massive. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
